ArticleFoods (Basel, Switzerland)2026
Theabrownin from Pu-erh Tea Restores Intestinal Immunity via Gut Microbiota-Metabolite Network in Immunosuppressed Mice.
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Theabrownin (TB), a polymeric pigment derived from ripened Pu-erh tea, demonstrates beneficial effects on lipid reduction, weight management, and mitigation of metabolic syndrome. However, the role of TB in restoring immune function in vivo has not been studied. This study evaluated the therapeutic effects and underlying mechanisms of TB in cyclophosphamide (CTX)-induced immunosuppressed mice. TB was administered at doses of 1.215, 0.608, and 0.304 mg/kg body weight, with levamisole hydrochloride (40 mg/kg) serving as a positive drug control. Each experimental group comprised eight mice. Evaluations primarily consisted of histopathological examination, enzyme-linked immunosorbent assay, Western blotting, flow cytometry, 16S rRNA sequencing, and ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)-based untargeted metabolomics. The results demonstrate that high- and medium-dose TB treatment significantly alleviated immunosuppression, as evidenced by restored body and organ weights, colon length, splenic and colonic histoarchitecture, blood cell counts, and immunoglobulin levels. These improvements correlated with upregulated colonic cytokines, claudin-1, occludin, toll-like receptor 2/4, and reduced regulatory T cell populations. High- and medium-dose TB treatment also enriched beneficial gut microbiota, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.